SpliceBio
@SpliceBioHQ
Followers
305
Following
148
Media
77
Statuses
173
Genetic medicines company harnessing Protein Splicing to develop the next-gen of gene therapies. Based on technology developed in the Muir Lab at @Princeton.
Barcelona
Joined February 2018
SpliceBio takes over Times Square! 🗽 Proud to see our $135M Series B milestone spotlighted on the iconic @Nasdaq Tower. Huge thanks to our team & investors powering the next wave of genetic medicines! 💡
0
0
3
Our co-founder and CEO traveled to Vienna this week to participate in a dynamic panel of strategic advisors discussing our pivotal $135M Series B financing. Great conversation, amazing energy and a big thank you to everyone at #BioEurope2025!
0
0
1
CEO, Miquel Vila-Perello, will join a panel of strategic investors who played a key role in our pivotal $135M Series B financing at #BIOEurope in 📍Vienna, Austria. Learn more: https://t.co/iFl2Gvz1S2
0
0
2
We're a finalist for the 2025 European #LifestarAwards in two categories: ‘Biotech of the Year’ & ‘Best Series B Raise!’ This honor underscores our mission to develop the next-gen of #genetherapies & inspires us to keep pushing the boundaries of what’s possible for patients.
0
0
0
#StargardtDisease blurs central vision and can ultimately cause blindness. With no approved treatments available, we’re addressing this unmet need with our lead program SB-007, the first dual AAV gene therapy in clinical development. #BlindnessAwarenessMonth
0
0
0
#ICYMI: SpliceBio’s VP of Clinical Operations, John Tobin and Sr. Director of Clinical Development, Feride Sahin, joined The @CarrollCenter for the Blind for a live discussion on our gene therapy approach in #stargardtdisease. Watch here ➡️
0
0
1
As #ESGCT2025 wraps up, our team is feeling energized and inspired! Connecting with colleagues and partners reinforces why our mission to develop the next generation of #genetherapies is so important.
0
0
3
SpliceBio CEO looks forward to speaking on The Company View panel during #CGMesa25's pre-conference ARM CEO and Investor Summit. We look forward to connecting with industry professionals and peers in Phoenix on Sunday and throughout the week!
0
0
0
We’re thrilled to be shortlisted for the 2025 #ScripAwards in the Business Development Team of the Year category! Congratulations to the SpliceBio Team and all of the finalists. We are looking forward to celebrating in December! Learn more ➡️ https://t.co/CEjO8XrGMr
0
0
1
We are excited to join @CarrollCenter's upcoming webinar, “Pioneering a Novel Gene Therapy for #StargardtDisease,” on 📅October 2nd at 12pm ET! Learn more and register here: https://t.co/ynP8Sqi9B0
0
0
1
From academic research to leading a global biotech company focused on innovative #genetherapy treatments, hear from SpliceBio’s co-founder and CEO, Miquel Vila-Perello, on the #ClinicalTrialblazers podcast. Tune in here ➡️
0
0
0
We're proud to sponsor the International Society for Genetic Eye Diseases and Retinoblastoma (ISGEDR) Congress in Oslo, Sept 11-13! Learn more ➡️ https://t.co/hD0gkkxU5l
0
0
1
Are you heading to #ATE2025 in📍Barcelona, Sept 2–4? Our CEO & CBO will be speaking across multiple sessions from building an investor-ready biotech to funding strategies and emerging #genetherapy technology. Learn more: https://t.co/yoYbaYw0hg
1
2
3
📢 #SpliceBio features on #OptimumTV with EQT Life Sciences! 📺 Go behind the scenes of our $135M Series B + discover how our Protein Splicing technology sets us apart in gene therapy. Hear from our CEO & EQT Life Sciences👇
Everyone knows the financing environment is tough right now. But that hasn’t stopped @SpliceBioHQ securing $135m in a Series B to advance its genetic medicines, including its lead programme SB-007 for the eye condition #Stargardt disease. Watch Miquel Vila- Perelló talk to
0
0
2
Don’t miss @CataloniaHealth’s BBQ 2025! ☀️#SpliceBio is proud to be a sponsor of this key biotech event. Join 400+ health innovators for an evening of networking & celebration! 📅 July 10 📍 Barcelona #Biotech #LifeSciences
0
0
2
📽️ Tune in to @CGT_Insights's webinar to hear from our VP of Regulatory Affairs & Quality, Leigh Shaw! A panel of experts will explore the evolving CGT regulatory landscape with a focus on patient safety. 📅 1 July | 🕓16:00 BST / 17:00 CEST 🔗 Register: https://t.co/LqfN9EH3gS
0
0
1
#Stargardtdisease patients currently have no approved treatments for this inherited retinal disorder. Our lead gene therapy, SB-007, is designed to address the underlying genetic cause of the disease with the potential to treat all patients. Discover more: https://t.co/XSKL2rBRem
0
0
2
Yesterday, we announced the close of a $135M Series B financing to support clinical development of SB-007 for #StargardtDisease, including the ongoing Phase 1/2 ASTRA and POLARIS studies. Stay tuned as we advance our broader pipeline of genetic medicines. https://t.co/XSKL2rBRem
0
2
4
Venue at capacity for @UKEyeGenetics annual conference @StAnnesCollege, Oxford! It is an exciting time to be involved in #ophthalmicgenetics. The diagnostic precision and therapeutic development are at an all-time peak! 👀🧬 We are grateful to our platinum sponsors @SpliceBioHQ
1
4
6
Enjoying a stimulating day of updates in #ophthalmicgenetics the UK Eye Genetics Group annual conference @StAnnesCollege, Oxford! A huge thank you to our platinum sponsor @SpliceBioHQ and our bronze sponsor @Metrovision for their amazing support! #ophthalmology #genetics
1
1
4